Daily Briefing – June 6: Hot payrolls break the soft-landing trade, semis suffer a real AI reset, Marvell joins the S&P 500 and biotech returns to evidence, FDA timing and cash discipline

The June 6 briefing is a weekend reset after a sharp change in tone. The U.S. May jobs report is no longer a pending macro risk: it landed stronger than expected, with nonfarm payrolls rising by 172,000 and unemployment unchanged at 4.3%. That was enough to push yields and rate-hike anxiety higher, turning Friday into a broad risk-off session and ending Wall Street’s nine-week winning streak. The damage was concentrated in technology and semiconductors, where the AI trade finally met a cleaner valuation shock. Broadcom’s disappointing AI-related reaction became the spark, but the selloff spread quickly through Nvidia, AMD, Intel, Micron, Marvell and the broader chip complex. The message is not that the AI infrastructure theme is dead; it is that the market has moved from “AI demand is strong” to “AI demand must beat very high expectations, support stretched multiples and survive higher discount rates.” Marvell remains one of the most important follow-through names because it is now set to join the S&P 500 before trading on June 22, adding a passive-flow and benchmark-inclusion angle to the custom-silicon story. Macro is also less forgiving. A stronger labor print reduces the urgency for Fed easing, keeps the dollar and yields in focus, and leaves small caps and biotech exposed if financial conditions tighten. Oil and Middle East risk still matter, but the immediate trading read is simpler: June 6 is about digesting Friday’s shock, separating durable AI infrastructure winners from crowded momentum trades, and rebuilding biotech watchlists around actual regulatory catalysts, cash runway, dilution risk and evidence quality after ASCO.

• AVGO— Broadcom remains the center of the AI valuation reset after a disappointing post-earnings reaction spread from one stock into the broader semiconductor tape.AI Earnings
• MRVL— Marvell is now both an AI custom-silicon momentum name and an index-flow story after S&P Dow Jones Indices selected it for S&P 500 inclusion before the open on June 22.AI / Index
• NVDA— Nvidia remains the anchor of the AI trade, but Friday’s selloff showed that even the strongest leader can be dragged lower when yields rise and chip multiples compress.AI Anchor
• AMD / INTC— AMD and Intel remain breadth checks for the semiconductor complex; after the chip-index washout, follow-through matters more than narrative catch-up.Chip Breadth
• MU / WDC / STX / NTAP— Memory, storage and data-movement names remain tied to AI infrastructure, but Micron’s sharp weakness shows how fast pressure can move through the data layer.Data Layer
• CIEN / ANET / CSCO— Networking and optical names stay relevant because AI factories need faster links and switching, but the group must now prove demand can overcome a colder multiple environment.Networking
• DELL / HPE / SMCI— AI server names remain the real-demand checkpoint because the market wants proof that capex converts into backlog, margins, deployments and sustainable orders.AI Servers
• VRT / ETN / GEV— Power, cooling and grid infrastructure remain strategic AI beneficiaries because data-center growth is constrained by electricity, thermal capacity and grid upgrades.Power / Cooling
• GOOGL / MSFT / AMZN— Hyperscalers remain central to the AI capex debate because their cloud budgets, custom chips and data-center spending define demand for the entire supply chain.AI Capex
• GME— GameStop remains a retail-flow and special-situation watch after its quarterly update and new $2 billion share repurchase authorization kept the name active.Retail / Buyback
• PHAR— Pharming remains a fresh FDA-calendar name after FDA acceptance of the Joenja/leniolisib pediatric sNDA resubmission for APDS in children aged 4 to 11, with an October 24, 2026 PDUFA date.FDA / Rare Disease
• URGN / TEVA— UroGen and Teva remain on the legal/IP watchlist after the JELMYTO patent-litigation settlement, which allows a potential Teva generic entry beginning September 15, 2030 if approved by FDA.Legal / IP
• IDYA— IDEAYA remains one of the cleaner post-ASCO regulatory stories because darovasertib plus crizotinib has a visible metastatic uveal melanoma path, but FDA alignment remains the key filter.ASCO / Regulatory
• IMRX— Immuneering remains a pancreatic cancer validation story after ASCO, but Friday’s risk-off tape makes Phase 3 design, cash runway and financing discipline more important.ASCO / Pancreatic
• NXTC— NextCure remains an early ADC watch around SIM0505 and CDH6, but the market will demand more mature patient numbers, safety clarity and capital visibility.ASCO / ADC
• IMTX— Immatics remains one of the stronger institutional cell-therapy stories from ASCO, with PRAME TCR-T execution and the SUPRAME Phase 3 path still central.ASCO / Cell Therapy
• ACTU— Actuate remains a pancreatic cancer biomarker-validation watch; randomized Phase 2 signals help, but the next trading layer is Phase 3 design, funding and timing.ASCO / Biomarker
• BCTX— BriaCell remains high beta after ASCO; biomarker and survival signals matter, but the decisive event remains the unblinded Bria-ABC Phase 3 readout.ASCO / Breast
• COGT / BBIO / VERA / CORT / CELC / CAPR— The FDA catalyst basket remains important because higher yields usually make biotech more selective, increasing the premium on clean PDUFA timing, label setup and cash runway.PDUFA Watch

• Payrolls landed hot— May nonfarm payrolls rose by 172,000 and unemployment stayed at 4.3%, shifting the debate away from rate cuts and toward higher-for-longer or even renewed hike risk.Jobs
• Yields matter again— The strong labor print pushed investors to reprice Fed risk, which is especially painful for long-duration growth, small caps and cash-burning biotech.Rates
• Nasdaq shock— Friday’s tech-heavy selloff was not a normal pause: the Nasdaq lost more than 4%, and the semiconductor complex took the hardest hit.Tech
• SOXX stress test— The chip tape suffered one of its worst sessions since the pandemic era, making Monday’s follow-through critical for AI sentiment.Semis
• AI is not broken, but stricter— The infrastructure theme remains real, but the market is now demanding upside, margin protection, guidance strength and valuation discipline at the same time.AI Valuation
• Oil still matters— Middle East risk keeps crude and inflation expectations relevant, but the immediate equity driver is the combination of hot jobs, rising yields and AI profit-taking.Oil / Geo
• Dollar and yen watch— A firmer dollar and yen weakness near key intervention-sensitive levels remain liquidity signals for global risk appetite.FX
• Healthcare may rotate— If tech stays under pressure, healthcare can attract defensive and catalyst-driven flows, but weak small-cap breadth would still hurt speculative biotech.Rotation
• ASCO digestion continues— Biotech is past the easy headline stage. The tape is separating registrational paths from early signals, biomarker stories and single-arm datasets.Biotech
• FDA policy watch— FDA’s draft guidance on leveraging prior knowledge in cell and gene therapy development remains constructive for rare-disease sponsors, but company-specific approvability still matters.Regulatory
• Small-cap filter— IWM and XBI are the breadth checkpoints. If they lag while mega-cap AI tries to stabilize, the rally remains narrow and fragile.Breadth
• Weekend risk— After a sharp Friday selloff, Monday’s open will test whether investors treat the move as a healthy reset or the start of a deeper derisking phase.Tape